Q3 Earnings Estimate for Imunon Issued By Zacks Research

Imunon, Inc. (NASDAQ:IMNN) – Equities researchers at Zacks Research issued their Q3 2026 earnings estimates for shares of Imunon in a research note issued to investors on Thursday, May 14th. Zacks Research analyst D. Bautz anticipates that the company will post earnings of ($0.87) per share for the quarter. The consensus estimate for Imunon’s current full-year earnings is ($3.44) per share. Zacks Research also issued estimates for Imunon’s Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($3.25) EPS, FY2027 earnings at ($2.00) EPS and FY2028 earnings at ($1.84) EPS.

IMNN has been the topic of several other reports. Maxim Group set a $10.00 target price on shares of Imunon and gave the stock a “buy” rating in a research report on Friday, April 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Imunon in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $10.00.

Imunon Stock Performance

Shares of NASDAQ IMNN opened at $2.26 on Tuesday. The firm has a market capitalization of $9.50 million, a P/E ratio of -0.44 and a beta of 2.04. Imunon has a one year low of $2.22 and a one year high of $41.22. The company’s fifty day moving average is $2.92 and its two-hundred day moving average is $3.41.

Imunon (NASDAQ:IMNN) last issued its earnings results on Tuesday, May 12th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.38.

Institutional Investors Weigh In On Imunon

Several institutional investors and hedge funds have recently made changes to their positions in IMNN. Riverview Capital Advisers LLC boosted its position in shares of Imunon by 193.3% in the 3rd quarter. Riverview Capital Advisers LLC now owns 34,364 shares of the company’s stock worth $176,000 after buying an additional 22,649 shares in the last quarter. DRW Securities LLC boosted its position in shares of Imunon by 6.9% in the 4th quarter. DRW Securities LLC now owns 58,830 shares of the company’s stock worth $224,000 after buying an additional 3,803 shares in the last quarter. Finally, Armistice Capital LLC purchased a new stake in shares of Imunon in the 4th quarter worth about $1,017,000. 4.47% of the stock is currently owned by hedge funds and other institutional investors.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.